亚洲中文久久精品无码_av在线无码播放_91精品久久综合_先锋成在线人资源视频

中文

Products

Location:Home > Products > GE
GE

Biacore T200、the versatile SPR system

Biacore T200 is a versatile system for high-quality characterization of molecular interactions, all the way from research to discovery and quality control
Share:

Back to product list
Detailed introduction

       One platform for comprehensive characterization of molecular interactions in terms of kinetics, affinity, specificity, comparability, concentration, immunogenicity, and thermodynamics

       Reliable ligand-binding assays, even for the most complex biologics

       Confident selection and characterization of the smallest organic compounds to large multidomain proteins

       Validated software meeting your regulatory expectations by supporting GxP procedures and 21 CFR Part 11 compliance

Fast, simple kinetic analysis

Biacore T200 software offers a range of tools for confident and reliable kinetic analyses. These analyses can be performed using a multicycle approach (many samples against one ligand or when different ligands are immobilized), or alternatively, using singlecycle kinetics (fast runs without regeneration).

 

Confident concentration analysis – with or without standards

Software-supported direct binding and inhibition assays enable measurement of active concentration. The precision and automation of the system generates highly reproducible data. Calibration-free concentration analysis (CFCA) is of great value when no satisfactory calibration standard is available.

 

Secure assays to meet regulatory needs

The widely adopted Biacore T200 offers reliable ligand-binding assays—as described in regulatory guidelines—to characterize and assess comparability, even for the most complex biologics. An optional GxP Package allows Biacore T200 to integrate seamlessly into GMP/GLP-regulated workflows.

 

Dedicated support for immunogenicity testing

The software provides dedicated tools for immunogenicity testing for confident detection and characterization of anti-drug antibodies (ADA) during preclinical and clinical development.